Depakote vs Lamictal

How they're similar

Both drugs started life as antiepileptics and are still used for seizures. Both were later approved for use in bipolar disorder, though for different aspects of it. Both are available as inexpensive generics. Both are oral medications taken daily. Neither is a controlled substance. Both are used off-label for a range of conditions, including certain chronic pain syndromes and, in valproate's case, migraine prevention.

Both drugs affect the same overall category of channels and neurotransmitters, though through different pathways. Both stabilize neuronal firing, which is why they work in seizures, and both dampen the excitability of neurons in mood networks, which is why they help in bipolar. Neither drug is a dopamine blocker, so neither causes the movement side effects, the prolactin elevation, or the metabolic weight gain that come with antipsychotics.

Both share the antiepileptic drug class warning about suicidal thoughts, which was added to the label of nearly every AED after FDA analyses in 2008. The risk is real but small, and it doesn't stop these drugs from being used routinely in bipolar disorder. Both need dose adjustments in some situations, though the specifics differ. Both have interactions worth knowing about, and one of the biggest is with each other.

How they differ

Valproate is a broad-spectrum drug with effects on GABA, sodium channels, and gene expression through histone deacetylase inhibition. It treats acute mania well, often within 5 to 7 days of reaching a therapeutic level. It's approved for acute mania and mixed episodes in bipolar I. It doesn't have a strong indication for bipolar depression, though it's used for maintenance in some settings.

Lamotrigine is a sodium channel blocker and glutamate modulator with a much narrower clinical role in mood. It's approved for maintenance treatment of bipolar I disorder, specifically to prevent depressive episodes. It doesn't work well for acute mania and shouldn't be used as a rescue medication for a manic episode. It also doesn't do much for acute depression. Its role is prevention, and it works best at delaying the next depressive relapse.

The titration difference is one of the most important practical differences. Valproate can be loaded quickly in an acute mania situation. A 15 to 20 mg/kg loading dose is not unusual in the hospital, and levels can be therapeutic within a couple of days. Lamotrigine has to be started very slowly because of the risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which are severe, sometimes fatal skin reactions. The standard adult titration is 25 mg daily for 2 weeks, then 50 mg daily for 2 weeks, then 100 mg daily for 1 week, then 200 mg daily. That's six weeks to get to a target dose that some people need higher than, and the timeline is not negotiable. Fast titration significantly raises SJS risk.

The valproate interaction changes lamotrigine dosing meaningfully. When lamotrigine is added to someone already on valproate, the lamotrigine starting dose is halved (25 mg every other day for the first 2 weeks) and the titration is stretched out further, usually reaching a target of 100 mg daily rather than 200. This is because valproate inhibits the UGT enzymes that clear lamotrigine, effectively doubling lamotrigine levels. Missing this interaction can push lamotrigine into toxic ranges and raise SJS risk.

Side effect tendencies

Lamotrigine is generally well-tolerated once past titration. It's weight-neutral for most people, doesn't cause the sedation and cognitive slowing that some anticonvulsants do, and doesn't require routine blood level monitoring. Common side effects include headache, dizziness, insomnia, and nausea, mostly during titration and mostly mild. Some people report cognitive clarity that they don't get on other mood stabilizers, though whether that's a real drug effect or just the absence of the effects other drugs cause is hard to know.

The SJS/TEN risk is the reason lamotrigine has to be started slowly. The risk is highest in the first 8 weeks of treatment and is much higher with fast titration, with valproate co-administration without a dose adjustment, and in children. Any rash during the titration period, especially in the first 8 weeks, is treated as a possible warning sign, and lamotrigine is usually stopped immediately until the rash can be evaluated. Most rashes turn out to be benign, but the cost of missing an SJS case is so high that the low threshold is warranted.

Valproate has a different set of concerns. Weight gain is common, sometimes significant, sometimes 10 to 20 pounds over months. Hair thinning and alopecia are common, often improving with zinc or selenium supplementation. Tremor is common at therapeutic levels. Thrombocytopenia (low platelets) is common at higher levels and usually mild. Hepatotoxicity is rare but serious, most often in children under 2 or in people with underlying liver disease. Pancreatitis is rare but possible. In women of reproductive age, PCOS-like features (irregular periods, hyperandrogenism, insulin resistance) are a real long-term concern.

Pregnancy is one of the biggest differences. Valproate is contraindicated in pregnancy in most cases because of a 2 to 5 percent risk of neural tube defects and clear evidence that in-utero exposure reduces IQ in exposed children. It's also linked to autism spectrum disorder in exposed children. Lamotrigine is considered one of the safer mood stabilizers in pregnancy, without clear evidence of major malformation risk at therapeutic doses. That said, lamotrigine levels drop significantly during pregnancy because of hormonal effects on clearance, and doses often need to increase in the second and third trimesters, then decrease again after delivery.

Interactions matter for both. Valproate is a substrate for CYP2C9 and 2C19 and inhibits several enzymes. The interaction with lamotrigine is the classic one. Lamotrigine is metabolized by UGT enzymes and is affected by valproate (levels rise) and by estrogen-containing contraceptives (levels fall by roughly half). Starting or stopping an oral contraceptive on lamotrigine often requires a dose adjustment. Pregnancy also drops lamotrigine levels, sometimes dramatically.

What tips the choice

The type of bipolar picture usually points strongly. Someone in acute mania needs valproate (or lithium, or an antipsychotic). Lamotrigine isn't the drug for that moment. Someone whose bipolar picture is dominated by depressive episodes, with less frequent or milder manias, is often a lamotrigine candidate. The prevention of depressive relapse is what lamotrigine does best.

Long-term use planning matters too. For someone who wants a mood stabilizer with low side effect burden and no routine blood monitoring, lamotrigine is often preferred. For someone who needs a drug that treats both manic and depressive episodes acutely, valproate has the broader coverage. Combination therapy (both together) is common, especially when the bipolar picture has both manic and depressive elements. In that case, the interaction has to be respected and dosing has to be adjusted.

Pregnancy planning shifts the balance sharply. For a woman of childbearing potential, lamotrigine is often preferred over valproate for anything long-term, and valproate is often avoided unless there's no reasonable alternative. Reliable contraception is part of any valproate plan in this group, and any pregnancy plan involves both psychiatry and OB.

Prior response is worth weighing. Someone who did well on valproate in the past often does again. Someone who couldn't tolerate lamotrigine because of a rash may still tolerate it a second time with a slower re-titration, though many clinicians and patients don't want to try. Someone who had a documented SJS reaction can't take lamotrigine again.

Cost isn't usually a factor since both are inexpensive generics. Formulary preferences vary, but both are widely covered.

Common questions

Why does lamotrigine take so long to titrate? Because of the Stevens-Johnson syndrome risk. SJS is a severe, sometimes fatal skin reaction, and the risk goes up dramatically with fast titration. The 6-week schedule of 25, then 50, then 100, then 200 mg isn't a suggestion. It's the safety-tested protocol, and shortcuts significantly raise the risk. If it feels frustratingly slow, that's the reason.

What happens if I get a rash on lamotrigine? Any rash during the first 8 weeks is treated seriously. The medication is usually stopped immediately, and the rash is evaluated by a clinician. Most rashes turn out to be benign viral or contact reactions, but the cost of missing SJS is severe enough that the caution is warranted. If SJS or TEN is diagnosed, lamotrigine can never be used again.

Can I take both at the same time? Yes, and it's a common combination in bipolar disorder. Valproate covers the mania side and lamotrigine covers the depression prevention side. But because valproate doubles lamotrigine levels, the lamotrigine dose needs to be about half of what it would be without valproate, and the titration is even slower. Missing this interaction is a real safety issue.

Which one is safer in pregnancy? Lamotrigine, by a large margin. Valproate is contraindicated in pregnancy in most cases because of the 2 to 5 percent risk of neural tube defects and the clear evidence of IQ effects on exposed children. Lamotrigine is considered one of the safer mood stabilizers in pregnancy, though levels drop significantly and doses often need to increase during the pregnancy.

Do I need blood work on either? Valproate needs level monitoring (target 50 to 125 mcg/mL) along with periodic LFTs and CBC. Lamotrigine does not need routine blood level monitoring under normal conditions, which is one of its practical advantages. Levels can be checked when there's a reason (pregnancy, adding an interacting drug, unexplained side effects), but there's no scheduled monitoring the way there is with valproate or lithium.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Valproate/divalproex sodium prescribing information.
2. U.S. Food and Drug Administration. Lamotrigine (Lamictal) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Bipolar disorder.